NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY Investor JP Morgan Presentation January 2020 Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forwardlooking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our cash runway, our advancement of our clinical trials, the results of our ...